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Cyclooxygenase-2 is a key enzyme in the conversion
of arachidonic acid to prostaglandins. The overex-
pression of cyclooxygenase-2 has been reported in
skin cancer cells, and may be involved in carcino-
genesis. Prostaglandin E2, the end product of
cyclooxygenase-2-induced catalysis, autoampli®es
the cyclooxygenase-2 expression. It is suggested that
an anti-mycotic drug, ketoconazole may inhibit car-
cinogenesis. We herein investigated if ketoconazole
may inhibit prostaglandin E2-induced cyclooxygen-
ase-2 expression in human epidermoid carcinoma A-
431 cells. Ketoconazole suppressed prostaglandin E2-
induced cyclooxygenase-2 protein and mRNA
expression and promoter activation in A-431; the
suppressive effects of ketoconazole were counter-
acted by cyclic adenosine monophosphate analog.
Analyses using deleted or mutated cyclooxygenase-2
promoters revealed that cyclic adenosine monopho-
sphate response element (± 59 to ± 53 bp) on the pro-
moter was involved in prostaglandin E2-induced
stimulation and ketoconazole-induced inhibition of
the promoter activity. Electrophoretic mobility shift
assays indicated that cyclic adenosine monopho-
sphate response element binding protein and activat-
ing transcription factor-1 may constitutively bind to
cyclic adenosine monophosphate response element
on cyclooxygenase-2 promoter. Prostaglandin E2
increased the proportion of phosphorylated forms
among total bound cyclic adenosine monophosphate
response element binding protein/activating tran-
scription factor-1, and the effect was suppressed by
ketoconazole. Prostaglandin E2 induced the phos-
phorylation of cyclic adenosine monophosphate
response element binding protein and activating
transcription factor-1, and the phosphorylation was
suppressed by cyclic adenosine monophosphate-
dependent protein kinase (protein kinase A) inhibi-
tor, indicating protein kinase A-mediated phos-
phorylation. Ketoconazole suppressed the prosta-
glandin E2-induced phosphorylation of cyclic adeno-
sine monophosphate response element binding
protein/activating transcription factor-1. Prosta-
glandin E2 increased intracellular cyclic adenosine
monophosphate level by activating adenylate cyclase
in A-431, and the increase was suppressed by ketoco-
nazole. These results suggest that ketoconazole may
suppress prostaglandin E2-induced cyclooxygenase-2
expression by inhibiting the cyclic adenosine mono-
phosphate signal in A-431, and stress its anti-cancer
effect. Key words: activating transcription factor-1/cyclic
adenosine monophosphate response element binding protein/
phosphorylation. J Invest Dermatol 119:174±181, 2002
I
t is reported that prostaglandin (PG) E2 is involved in the
progression of skin cancers; PGE2 induces cancer cell
proliferation, inhibits apoptosis (Tsuji and DuBois, 1995),
promotes angiogenesis (Gallo et al, 2001), and inhibits
immune surveillance in cancers of several tissues, including
skin (Sheng et al, 1998; Higashi et al, 2000). PGE2 synthesis is
enhanced in skin cancers (Muller-Decker et al, 1995; Kagoura et al,
2001). The synthesis of prostaglandins is dependent on the activity
of cyclooxygenase (COX), which converts arachidonic acid to
PGH2, the common precursor to all prostaglandins. There are two
isoforms of COX: COX-1 and COX-2. COX-1 is constitutively
expressed in most cell types, whereas COX-2 expression is basally
at low level in most tissues, but is induced by phorbol esters,
bacterial endotoxins, or growth factors (Tang et al, 2001). It is
reported that COX-2 expression is enhanced in skin cancers,
especially squamous cell carcinoma (Muller-Decker et al, 1999;
Gallo et al, 2001), which is considered to be the cause of PGE2
overproduction (Muller-Decker et al, 1995). A recent study
reported that the suppression of COX-2 expression led to
inhibition of the growth of human skin cancer (Higashi et al,
2000). It is thus a key therapeutic target for skin cancer to prevent
COX-2 expression.
It is reported that PGE2, the end product of COX-2, promotes
the expression of its own synthesizing enzyme COX-2 in human
airways smooth muscle cells (Bonazzi et al, 2000), human
monocytes (Hinz et al, 2000), murine keratinocytes (Maldve et al,
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2000), and especially in human prostate, breast, and colon
carcinoma (Tjandrawinata et al, 1997). Such autoregulatory action
of PGE2 may be mainly mediated by inducing 3¢,5¢-adenosine
cyclic monophosphate (cAMP) signal as cell surface PGE2
receptors, EP2 and EP4, are positively coupled to adenylate cyclase
(AC), which synthesizes cAMP (Negishi et al, 1993; Hinz et al,
2000). The other cAMP-elevating agents, such as forskolin or
adenosine A2a receptor agonist also promoted COX-2 expression
in rat microglia (Fiebich et al, 1996), which also supports the
cAMP-induced COX-2 expression. The human COX-2 promoter
contains cAMP response element (CRE) (± 59 to ± 53 bp relative
to the transcriptional start site) (Inoue et al, 1994), and this element
may be involved in PGE2-induced COX-2 gene expression (Hinz
et al, 2000). As COX-2 mRNA is highly degradable and unstable
due to the AU-rich sequences in 3¢-untranslated region (Ristimaki
et al, 1994), the autoampli®cation of COX-2 expression by PGE2
may sustain the enzyme levels in human prostate, breast, and colon
carcinoma (Tjandrawinata et al, 1997). To suppress this auto-
ampli®cation by PGE2 may therefore lead to the inhibition on the
growth of cancer cells.
Recently it has been reported that an anti-mycotic ketoconazole
is therapeutically effective for cancers in several tissues, including
skin (Trachtenberg and Pont, 1984; Janssen et al, 1989).
Ketoconazole inhibited cytochrome P450-dependent enzyme 11-
hydroxylase (Loose et al, 1983), which suppressed testosterone
production and resulted in the inhibition on the growth of
testosterone-dependent prostate cancer (Trachtenberg and Pont,
1984). Ketoconazole also inhibits the activity of P450-dependent
aryl-hydrocarbon-hydroxylase or 7-ethoxyresoru®n-deethylase in-
volved in the synthesis of carcinogens and thus reduces the skin
carcinogenic potential (Janssen et al, 1989). Ketoconazole also
inhibits the activity of the other enzymes such as AC (Stalla et al,
1988), 5-lipoxygenase (Bettens et al, 1986), or calmodulin-
dependent enzymes (Wolff et al, 1993). A recent study reported
that ketoconazole inhibited arachidonic acid-induced COX-2
expression in rat intestinal epithelial cells by inhibiting the
monoxygenase-catalyzed synthesis of 14,15-epoxyeicosatrienoic
acid, the direct inducer of COX-2 expression, from arachidonic
acid (Peri et al, 1998); however, it is unknown whether
ketoconazole may alter PGE2-induced COX-2 expression.
In this study, we investigated if ketoconazole may suppress
PGE2-induced COX-2 expression in human epidermoid carcino-
ma A-431 cells. We have obtained the inhibitory effects of
ketoconazole. We further analyzed the cis-elements on COX-2
promoter and the transcription factors responsible for the PGE2-
induced stimulation and ketoconazole-induced inhibition.
MATERIALS AND METHODS
Reagents Lipopolysaccharide from Escherichia coli (serotype 025:B6)
was obtained from Sigma (St Louis MO). Dibutyryl cAMP (Bt2cAMP),
N-[2-((p-bromocinnamyl)aminoethyl)-5-isoquinolinesulfonamide (H-89),
and 3-isobutyl-1-methylxanthine were obtained from Calbiochem (La
Jolla, CA). Ketoconazole was from Janssen Pharmaceutica N.V. (Beerse,
Belgium). Anti-c-Jun antibody, anti-COX-1 antibody, anti-COX-2
antibody, and anti-CCAAT/enhancer binding protein (C/EBP) d
antibody were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-cAMP response element binding protein (CREB) antibody,
anti-activating transcription factor-1 (ATF-1) antibody, and anti-
phospho-CREB/ATF-1 antibody recognizing both phosphorylated
CREB and ATF-1 were from New England Biolabs (Beverly, MA).
Cell line and culture conditions Human epidermoid carcinoma A-
431 cells were purchased from Dainippon Pharmaceutical (Osaka, Japan),
and were maintained in Dulbecco's modi®ed Eagle's medium (DMEM)
(Gibco/BRL, Grand Island, NY) supplemented with 10% fetal bovine
serum, 100 U penicillin per ml, and 100 mg streptomycin per ml.
Plasmids and transfections The phPES2 series of ®re¯y luciferase
constructs containing wild-type or mutated human COX-2 promoter
fragments were prepared and cloned into pGL3 basic vector (Promega,
Madison, WI) as described (Inoue et al, 1994, 1995; Inoue and Tanabe,
1998). p4x nuclear factor kB (NF-kB)-SV-luc, p4xC/EBP-SV-luc, and
p4xCRE-SV-luc were constructed by inserting four copies of NF-kB
sequences (5¢-GTGGGGACTACCCCCT-3¢), C/EBP sequences (5¢-
GGCTTACGCAATTTT-3¢), and CRE sequences (5¢-CATTTCGTC-
ACATGG-3¢) on COX-2 promoter, respectively, in front of minimal
SV40 promoter upstream of ®re¯y luciferase reporter as described
(Aronica et al, 1994; Maehara et al, 2000). Transient transfections were
performed using Lipofectamine Plus reagent (Gibco/BRL) according to
the manufacturer's protocol. Brie¯y, A-431 cells (2 3 105) were plated
in six-well plates the day before transfection and grown to about 90%
con¯uence. 1.8 mg of luciferase construct and 0.2 mg of Rous sarcoma
virus b-galactosidase vector per well was prepared in 100 ml serum-free
and antibiotic-free DMEM and incubated with 3 ml of Lipofectamine
Plus reagent at room temperature for 15 min, followed by addition of
2.5 ml of lipofectamine. After incubation at room temperature for
another 15 min, the mixture was added into wells containing 0.8 ml
DMEM. Transfections were allowed to proceed for 5 h and cells were
washed and incubated in serum-free DMEM for 18 h. Cells were
washed, and pretreated with serum-free DMEM alone or with 1 mM
ketoconazole in the presence or absence of 100 mM Bt2cAMP for
30 min, then treated with 1 mM PGE2 for 4 h in the presence or
absence of the above-mentioned reagents. In some experiments, cells
were also treated with 1 mg lipopolysaccharide per ml during the same
period. Cell extracts were prepared and luciferase activities were
quanti®ed using luciferase assay system (Promega). The same cell extracts
were assayed for b-galactosidase activity using chemiluminescent Galacto-
Light kit (Tropix, Bedford, MA). All readings were taken using a Lumat
9501 luminometer (Berthold, Wildbach, Germany). The results obtained
in each transfection were normalized for b-galactosidase activity and
expressed as relative luciferase activity.
Western blot analysis A-431 cells (4 3 105) were seeded on a 6 cm
Petri dish. When subcon¯uent, the cells were washed and incubated in
2 ml of serum-free DMEM for 24 h. The medium was then removed,
and cells were incubated in 1.5 ml of serum-free DMEM for a further
4 h. The cells were pretreated with ketoconazole at indicated
concentrations in the presence or absence of 100 mM Bt2cAMP for
30 min, then treated with 1 mM PGE2 in the presence or absence of the
above-mentioned reagents for 4 h. Cells were then lyzed in a buffer
containing 20 mM Tris±HCl (pH 7.5), 150 mM NaCl, 1 mM
ethyleneglycol-bis-(b-aminoethylether)-N,N,N¢,N¢-tetraacetic acid, 1%
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-
glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 50 mg aprotinin per ml,
50 mg leupeptin per ml, and centrifuged at 10 000 g for 10 min. Protein
concentration in the supernatant was determined by Bio-Rad DC
reagent (Bio-Rad Laboratories, Hercules, CA). For Western analysis,
20 mg of proteins were resolved on a 10% sodium dodecyl sulfate±
polyacrylamide gel. The proteins were transferred to a PVDF membrane
by electroblotting. The membrane was then blocked in 5% nonfat dry
milk TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween-20) at
room temperature for 1 h. Primary antibody was diluted at 1:1000 in 5%
bovine serum albumin/TBST for antibodies against phospho-CREB/
ATF-1, CREB, or ATF-1 or at 1:4000 for anti-COX-2 and anti-COX-
1 antibodies. The membrane was incubated at room temperature for 2±
3 h and washed 3 3 5 min with TBST, then developed by the
enhanced chemiluminescence system (Amersham, Arlington Heights, IL).
Quanti®cation was performed by scanning the blot into Photoshop
Adobe and performing densitometry with NIH Image Software.
Reverse transcription±polymerase chain reaction (reverse
transcription±PCR) A-431 cells were incubated as above for 2 h, and
total cellular RNA was extracted using mRNA puri®cation kit
(Pharmacia, Uppsala, Sweden) according to the manufacturer's
instructions. cDNA was made from RNA samples as described
(Tjandrawinata et al, 1997). Primer sequences for COX-2 and for the
internal control b-actin as well as PCR conditions are as described
(Tjandrawinata et al, 1997). The PCR products were analyzed by
electrophoresis on 2.5% agarose gels and stained with ethidium bromide,
viewed by ultraviolet light, and photographed. Densitometric analysis
was performed by scanning the bands into Photoshop and performing
densitometry with NIH Image Software. Results are expressed for
COX-2 product as the ratio relative to b-actin product.
Electrophoretic mobility shift assays The following sequences
derived from the human COX-2 promoter containing CRE were used:
PE2CRE1, 5¢-GAAACACTCATTTCGTCACATGG-3¢; PE2CRE2,
5¢-CAAGCCCATGTGACGAAATGA-3¢. They were annealed and 5¢-
overhangs were labeled by incorporation of [32P]deoxycytidine
triphosphate with Klenow DNA polymerase. For gel shift assays, 2±5 mg
of nuclear protein extracts were incubated at room temperature for
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5 min with a mixture containing 6 mM HEPES (pH 7.9), 0.4 mM
ethylenediamine tetraacetic acid, 125 mM KCl, 10% glycerol, 0.05 mg
poly dI-dC per ml, 1 mM dithiothreitol, 2.5 mM sodium pyrophosphate,
1 mM b-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 50 mg
aprotinin per ml, 50 mg leupeptin per ml. Approximately, 1 ng labeled
probe was added and the reactions were incubated at room temperature
for another 20 min. In antibody supershift experiments, the nuclear
extracts were preincubated with various amounts of antibodies on ice for
30 min before the addition of probe. Reactions were then fractionated
on a nondenaturing 5% polyacrylamide gel in 0.5 3 TBE (25 mM Tris±
HCl, 0.5 mM ethylenediamine tetra-acetic acid, 25 mM boric acid). The
gels were dried and visualized with phosphorimager (Molecular
Dynamics, Sunnyvale, CA).
PGE2 production A modi®cation of the method of Yanagi and
Komatsu (1976) was used. Brie¯y, 1 3 105 cells per well of A-431 were
plated in six-well plates and grown to 60% con¯uence in growth
medium. The cells were washed and serum-deprived as described above.
The cells were pretreated with serum-free DMEM alone or with 1 mM
ketoconazole for 30 min, then treated with 1 mM PGE2 in the presence
or absence of ketoconazole for 4 h. The cells were harvested and
suspended in 20 mM Tris±HCl (pH 7.4), containing 5 mM tryptophan
and sonicated. The sonicated cells were incubated for 2 min with 5 mM
[14C]arachidonic acid in 100 mM Tris±HCl (pH 8.0), 2 mM hematin,
and 5 mM tryptophan. After adding n-hexane ethyl acetate and
centrifuging the preparation at 1000 g for 10 min, the amount of
synthesized [14C]PGE2 in the aqueous phase was determined by
measuring radioactivity. Production of PGE2 was normalized to protein
concentrations.
Measurement of cAMP A-431 cells were cultured under the
indicated conditions, and were harvested and lyzed with ethanol. The
cell lysates were centrifuged and the supernatants were dried under
vacuum. The dried samples were dissolved in acetate buffer (pH 5.8),
and cellular cAMP contents were measured with enzyme-linked
immunosorbent assay (Amersham, Arlington Heights, IL) according to
the manufacturer's instructions. The sensitivity of the assay was 12 fmol
per assay well. The cellular cAMP level was presented as pmol/106 cells.
Assays of cAMP-dependent protein kinase (protein kinase A;
PKA) A-431 cells were cultured under the indicated conditions, and
were lyzed in the buffer containing 20 mM Tris±HCl (pH 7.4), 1 mM
ethylenediamine tetraacetic acid, 1 mg aprotinin per ml, 1 mg pepstatin
per ml, 1 mg leupeptin per ml, 15 mM benzamidine, and 3.75 mM b-
mercaptoethanol. The cell lysate was assayed for the activity of PKA
using an enzyme-linked immunosorbent assay kit (Medical and
Biological Laboratories, Nagoya, Japan) by examining the
phosphorylation of plate-bound peptide substrate in the presence or
absence of 2 mM cAMP for 10 min at room temperature. The plates
were sequentially incubated with biotinylated antibody to the
phosphorylated substrate, peroxidase-conjugated streptavidin, o-
phenylenediamine, then the reaction was stopped, and optical density at
492 nm was read. The net optical density was calculated by subtracting
the density in the presence of 1 mM of speci®c PKA inhibitor KT-5720
(Calbiochem) from the total density. The PKA activity was expressed as
an activity ratio, which is de®ned as the net optical density in the
absence of exogenous cAMP divided by the net optical density in the
presence of cAMP.
Measurement of AC activity The lysate of A-431 cells described
above was centrifuged at 23,600 3 g for 10 min. The pellet was used as
a particulate fraction for AC assays as described (Salomon et al, 1974;
Choi et al, 1992). The AC activity of the particulate fraction was
measured at 37°C for 10 min in 20 mM Tris±HCl (pH 7.4), 1 mM
[a-32P]adenosine triphosphate (30 Ci per mmol) (Amersham), 1 mM
[3H]cAMP, 1 mM 3-isobutyl-1-methylxanthine, 5 mM MgCl2, 0.2 mM
ethyleneglycol-bis-(b-aminoethylether)-N,N,N¢,N¢-tetraacetic acid,
20 mM creatine phosphate, and 100 units per ml creatine phosphokinase.
AC activity was presented as pmol cAMP formed per min per mg
protein.
Statistical analyses One-way analysis of variance with Scheffe's
multiple comparison test was used for the data in Figs 2±4 and 7.
RESULTS
The effects of ketoconazole on PGE2-induced COX-2
protein and mRNA expression COX-2 protein was
constitutively expressed in A-431 cells, and the expression was
enhanced by PGE2 (Fig 1a). The PGE2-induced enhancement of
COX-2 protein level was inhibited by ketoconazole in a
concentration-dependent manner with maximal inhibition at
1 mM, and the inhibition was counteracted by cAMP analog,
Bt2cAMP, indicating the involvement of cAMP in the
ketoconazole-induced inhibition. COX-1 protein expression was
not altered by PGE2, PGE2 + ketoconazole, or PGE2 +
ketoconazole + Bt2cAMP. As analyzed by reverse transcription±
PCR, the steady-state mRNA level for COX-2 was enhanced by
PGE2, and the enhancement was partially suppressed by
ketoconazole, which was also counteracted by Bt2cAMP (Fig 1b).
We then analyzed if the enhancement or inhibition of COX-2
expression may result in the increase or decrease of PGE2
production in A-431 cells, respectively. The incubation with
Figure 1. PGE2-induced COX-2 protein and mRNA expression,
and the ketoconazole-mediated inhibition on the expression. (a)
A-431 cells were preincubated for 30 min with medium alone or with
0.1, 1, or 10 mM ketoconazole in the presence or absence of 100 mM
Bt2cAMP, and then incubated with or without 1 mM PGE2 in the
presence or absence of above-mentioned reagents for another 4 h. Cells
were harvested, and proteins were extracted and analyzed by Western
blotting. The lower graph is the quantitation of each signal in the upper
immunoblot. Values are signal intensity relative to that in untreated cells
(control). (b) The cells were preincubated with medium alone or with
1 mM ketoconazole in the presence or absence of 100 mM Bt2cAMP for
30 min, then incubated with or without 1 mM PGE2 in the presence or
absence of above-mentioned reagents for 2 h. RNA was isolated, and
reverse transcription±PCR was performed. The intensity of the band for
COX-2 was corrected to that for b-actin. The lower graph shows the
corrected intensities relative to those in untreated cells (set as 1.0). The
results shown are representative of four separate experiments.
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PGE2 for 4 h increased PGE2 synthetic activity 4.1-fold of controls,
which was reduced by the coincubation with ketoconazole by 75%
(Fig 2); however, ketoconazole per se did not suppress PGE2
synthetic activity when added to the reaction mixture. Thus the
PGE2-induced stimulation and ketoconazole-induced inhibition of
COX-2 expression resulted in the increase and decrease of PGE2
synthetic activity in A-431 cells, respectively.
The effects of ketoconazole on PGE2-induced COX-2
promoter activation We then analyzed if ketoconazole may
suppress PGE2-induced upregulation of COX-2 promoter activity.
The activity of COX-2 promoter (±327 to +59) was increased by
PGE2 4.8-fold of controls, and the increase was suppressed by
ketoconazole, which was counteracted by Bt2cAMP (Fig 3b, the
left four columns). These indicate that PGE2-responsive and
ketoconazole-sensitive cis-elements may be located within the
region from ±327 to +59, and that cAMP may be involved in the
ketoconazole-induced suppression of the promoter activity.
Constructs with deletions were then used to analyze the PGE2-
responsive and ketoconazole-sensitive elements. Deletion of the
sequence up to ±124 did not signi®cantly affect the induction by
PGE2 and suppression by ketoconazole on the promoter activity,
although the deletion from ±220 to ±124 reduced the basal
promoter activity by 30%, indicating that the sequences between
±220 and ±124 may partially confer the basal promoter activity. As
the NF-kB element is located within the region ±327 to ±220, and
the C/EBP element is located within the region ±220 and ±124
(Fig 3a), the NF-kB and C/EBP sites may not be essential for the
induction by PGE2 and suppression by ketoconazole on the COX-
2 promoter activity, but C/EBP may be related to the basal
promoter activity. Deletion up to ±52 dramatically decreased the
basal promoter activity, and abrogated the induction by PGE2 and
the suppression by ketoconazole on the promoter activity. This
indicates that the sequences between ±124 and ±52, containing
CRE may be essential for basal promoter activity and PGE2-
induced promoter activity and also for the ketoconazole-induced
suppression. This proposition was further supported by constructs
containing site-directed mutations. The mutation of either NF-kB
or C/EBP site did not affect the PGE2-induced stimulation and
ketoconazole-induced suppression of COX-2 promoter activity,
although the latter mutation partially reduced (by 27%) the basal
promoter activity (Fig 3c). In contrast, the mutation of CRE site
Figure 3. The PGE2-induced stimulation of COX-2 promoter
and the effects of ketoconazole on the stimulation. (a) Schematic
representation of human COX-2 promoter. The locations of NF-kB, C/
EBP, and CRE are shown with their sequences, and the lower case
letters represent the mutations. The nucleotide positions are relative to
the transcriptional start site. (b) A-431 cells were transiently transfected
with 1.8 mg of a series of human COX-2 promoter deletion constructs
ligated to luciferase (±327/+59, ±220/+59, ±124/+59) and 0.2 mg b-
galactosidase vector. (c) A-431 cells were transfected with wild-type
COX-2 promoter luciferase construct (±327/+59) or mutant construct
derived from ±327/+59, and b-galactosidase vector. The mutations exist
at NF-kB, C/EBP, or CRE. After transfection, cells were allowed to
recover for 18 h and pretreated with medium alone or with 1 mM
ketoconazole in the presence or absence of Bt2cAMP 100 mM for
30 min, then treated with or without 1 mM PGE2 in the presence or
absence of the agents above for 4 h. Cells were harvested and luciferase
and b-galactosidase activities were measured. Relative luciferase activities
normalized to b-galactosidase activities were shown. The data are
mean 6 SEM of four separate experiments. The fold induction by PGE2
vs basal promoter activity and percentage inhibition by ketoconazole on
the PGE2-mediated induction are shown for each promoter. *p < 0.05
vs control values, and ²p < 0.05 vs values with PGE2 alone, by one-way
analysis of variance with Scheffe's multiple comparison test.
Figure 2. PGE2 synthetic activity in PGE2-treated A-431 cells and
the effects of ketoconazole on the activity. A-431 cells were
preincubated with medium alone or with ketoconazole 1 mM for
30 min, then incubated with or without 1 mM PGE2 in the presence or
absence of ketoconazole for another 4 h. The cells were harvested,
sonicated, and the cell sonicate was incubated with 10 mM
[14C]arachidonic acid for 2 min in the presence or absence of
ketoconazole 1 mM. The synthesis of [14C]PGE2 was measured and
normalized to protein concentrations. The data are mean 6 SEM of four
separate experiments. *p < 0.05 vs control values of cells with medium
alone, and ²p < 0.05 vs values with PGE2 alone, by one-way analysis of
variance with Scheffe's multiple comparison test.
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decreased the basal promoter activity by 80%, and abrogated the
induction by PGE2 and suppression by ketoconazole. These results
suggest that CRE on COX-2 promoter may be essential for the
basal activity. The CRE may also be the PGE2-responsive and
ketoconazole-sensitive element, although it is also possible that the
mutation of the basal activity-conferring element, CRE may
prevent the occurrence of any transcriptional activation either
through CRE or the other elements.
To determine if ketoconazole may inhibit PGE2-induced
activation of CRE-dependent gene transcription, A-431 cells
were transfected with plasmid containing four repeats of CRE in
front of the enhancerless minimal SV40 promoter and luciferase
reporter, and were incubated with PGE2 in the presence or absence
of ketoconazole. The enhancer activity of CRE was evaluated by
the relative luciferase activity in the lysates of the transfected cells.
The enhancerless SV40 promoter±luciferase vector produced very
low background luciferase activity, which was not altered by
PGE2 or PGE2 + ketoconazole (Fig 4). The enhancer activity
of CRE was constitutively high, which was increased by PGE2
5.1-fold (Fig 4). Ketoconazole inhibited the PGE2-induced
increase of CRE enhancer activity by 70%, and the inhibition
was counteracted by Bt2cAMP. The enhancer activity of NF-kB
was constitutively low, which was not altered by PGE2,
PGE2 + ketoconazole, or PGE2 + ketoconazole + Bt2cAMP.
The enhancer activity of C/EBP was not altered by these agents,
either. The enhancer activities of CRE, NF-kB, and C/EBP were
promoted by a positive control lipopolysaccharide, which is known
to enhance CRE, NF-kB, and C/EBP-mediated COX-2 gene
transcription (Inoue and Tanabe, 1998; Caivano et al, 2001). These
results suggest that ketoconazole may inhibit PGE2±induced COX-
2 transcription through CRE, and that cAMP may be involved in
the inhibitory effect of ketoconazole.
The transcription factors binding to COX-2 CRE To
identify transcription factors that bind to the COX-2 CRE,
electrophoresis mobility shift assays were performed. Incubation of
A-431 nuclear extracts with the COX-2 CRE probe produced the
DNA±protein complex band (Fig 5a,b), which was competed by
excess cold COX-2 CRE (Fig 5b). The binding activity of A-431
nuclear extracts to the COX-2 CRE did not change upon the
treatment with PGE2 alone or PGE2 + ketoconazole (Fig 5a,b).
Anti-CREB antibody potently and anti-ATF-1 antibody
moderately supershifted the band (Fig 5a), indicating that this
band contains CREB and ATF-1. Though it is reported that c-Jun
transcription factor (Hsue and Lai, 1995) or C/EBPd (Inoue et al,
1995) also binds to COX-2 CRE, neither anti-c-Jun nor anti-C/
EBPd antibody supershifted or cleared the band (Fig 5b),
indicating the absence of c-Jun or C/EBPd in the band. As the
phosphorylation of CREB and ATF-1 enhances their
transcriptional activity (Tang et al, 2001), it was examined
whether the phosphorylated CREB or ATF-1 in PGE2-treated
Figure 5. Electrophoretic mobility shift assay
targeting the CRE site. A-431 cells were
preincubated with medium alone or with 1 mM
ketoconazole for 30 min, then incubated with or
without 1 mM PGE2 in the presence or absence
of ketoconazole for 2 h, and nuclear extracts were
prepared. The nuclear extracts were incubated
with 32P-labeled oligonucleotides containing
COX-2 CRE site. Cold chase experiments were
performed with a 50-fold excess of a competitor
oligonucleotide (b). In supershift assays, antibodies
for CREB, ATF-1, phospho-CREB/ATF-1 (a)
or for c-Jun, C/EBPd (b) were incubated for
30 min before the addition of the probe. Arrows
indicate the DNA±protein complexes and
supershifted complexes.
Figure 4. PGE2-induced activation and ketoconazole-induced
inhibition on the enhancer activities of NF-kB, C/EBP, and
CRE. A-431 cells were transiently transfected with luciferase reporter
plasmids driven by NF-kB, C/EBP, or CRE together with b-
galactosidase vector. The cells were allowed to recover for 18 h and
preincubated with medium alone or with 1 mM ketoconazole in the
presence or absence of 100 mM Bt2cAMP for 30 min, then incubated
with or without 1 mM PGE2 in the presence or absence of reagents
above for 4 h. In parallel, the cells were also incubated with 1 mg
lipopolysaccharide per ml as a positive control during the same period.
The cells were then harvested and luciferase and b-galactosidase activities
were assayed. The results are shown as relative luciferase activities
normalized for b-galactosidase activities, and represent mean 6 SEM of
four separate experiments. *p < 0.05 vs control values, and ²p < 0.05 vs
values with PGE2 alone, by one-way analysis of variance with Scheffe's
multiple comparison test.
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samples may also bind to the COX-2 CRE, using the antibody
recognizing phosphorylated forms of both CREB and ATF-1. The
band supershifted by anti-phospho-CREB/ATF-1 is more obvious
in PGE2-treated samples than in control untreated samples, and the
supershift was reduced by ketoconazole treatment (Fig 5a). These
results indicate that CREB/ATF-1 may constitutively bind to
CRE, and that PGE2 may increase the proportion of
phosphorylated forms among total bound CREB/ATF-1
proteins, which may enhance the transcription through CRE.
Ketoconazole may suppress the PGE2-mediated increase of the
phosphorylated CREB/ATF-1 bound to CRE.
The effects of ketoconazole on PGE2-induced
phosphorylation of CREB/ATF-1 We examined if CREB
and ATF-1 may be phosphorylated by PGE2 treatment. PGE2
induced the phosphorylation of CREB and ATF-1 as early as
5 min after the treatment, and the phosphorylation was maximized
at 15 min and lasted about 1 h (Fig 6a). The PGE2-induced
phosphorylation was suppressed by cAMP-dependent protein
kinase (PKA) inhibitor H-89, indicating PKA-mediated
phosphorylation. The total level of CREB was not affected by
PGE2 or H-89 treatment. Ketoconazole suppressed the PGE2-
induced phosphorylation of CREB and ATF-1, and the
suppression was counteracted by Bt2cAMP (Fig 6b). These
results indicate that PGE2 may induce the phosphorylation and
resultant activation of CREB/ATF-1 via PKA, and that the
phosphorylation may be suppressed by ketoconazole.
The effects of ketoconazole on PGE2-induced cAMP signal
and AC activity PGE2 is known to increase intracellular cAMP
level (Negishi et al, 1993), and cAMP appeared to be involved in
the ketoconazole-mediated suppression of COX-2 induction by
PGE2. It was thus examined whether ketoconazole may alter the
PGE2-induced increase of the cAMP level. PGE2 increased the
cAMP level 9-fold of controls in A-431 cells 15 min after
treatment, and the level gradually decreased and returned to the
background at 90 min (Fig 7a). Ketoconazole suppressed the
PGE2-induced increase of cAMP level by 85% at 15 min. The
PGE2-induced cAMP signal appeared to increase the PKA activity
4-fold of the controls (Fig 7b), and the increase was also suppressed
by ketoconazole by 75%, which paralleled the inhibition of
CREB/ATF-1 phosphorylation (Fig 6b). The incubation with
PGE2 increased the activity of cAMP-synthesizing enzyme AC 5-
fold of controls in A-431 cells, and ketoconazole suppressed the
increase of AC activity by 83% (Fig 7c). These results suggest that
ketoconazole may suppress PGE2-induced cAMP signal by
inhibiting AC activity. The ketoconazole-induced inhibition of
Figure 6. The PGE2-induced phosphorylation of CREB/ATF-1
and ketoconazole-induced inhibition of the phosphorylation. (a)
A-431 cells were preincubated with medium alone or with 0.1 mM H-
89 for 30 min, then incubated with 1 mM PGE2 during the indicated
periods. Twenty micrograms of whole cell lysates were resolved on
sodium dodecyl sulfate±polyacrylamide gel and probed with an antibody
recognizing both phospho-CREB and phospho-ATF-1. A parallel blot
was probed with an antibody for total CREB. (b) A-431 cells were
preincubated with medium alone or with 1 mM ketoconazole in the
presence or absence of 100 mM Bt2cAMP for 30 min, then incubated
with or without 1 mM PGE2 for 15 min The phosphorylation of
CREB/ATF-1 in the cell lysates was analyzed as described above. The
results are representative of four separate experiments.
Figure 7. The effects of ketoconazole on cAMP level, PKA, and
AC activities in PGE2-treated A-431 cells. A-431 cells were
preincubated with medium alone or with 1 mM ketoconazole for
30 min, then incubated with or without 1 mM PGE2 in the presence or
absence of ketoconazole. The cells were harvested and assayed for cAMP
level during the indicated periods (a). PKA activity in the cell lysate (b)
or AC activity in the particulate fraction (c)was analyzed after 15 min of
incubation. The data are mean 6 SEM of four separate experiments.
*p < 0.05 vs control values, and ²p < 0.05 vs values with PGE2 alone,
by one-way analysis of variance with Scheffe's multiple comparison test.
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cAMP signal may lead to the inhibition of CREB/ATF-1
phosphorylation by PKA, and result in the suppression of PGE2-
induced COX-2 transcription in A-431 cells.
DISCUSSION
This study demonstrated that ketoconazole inhibited PGE2-
induced COX-2 expression in A-431 cells. PGE2 induced cAMP
signal in A-431 cells and thus enhanced the phosphorylation of
CREB/ATF-1 by cAMP-dependent protein kinase (PKA), which
led to the phospho-CREB/ATF-1-mediated COX-2 transcrip-
tion. Ketoconazole suppressed the PGE2-induced cAMP signal by
inhibiting AC, which resulted in the inhibition of CREB/ATF-1
phosphorylation by PKA, and then led to the inhibition of COX-2
expression. Although the ketoconazole-induced suppression of AC
has also been detected in human T cells (Kanda et al, 2001) or rat
anterior pituitary cells (Stalla et al, 1988, 1989), this study directly
shows that ketoconazole inhibits the phospho-CREB/ATF-1-
mediated gene expression. The present results also indicate that
ketoconazole may inhibit the phospho-CREB/ATF-1-mediated
expression of the other genes related to carcinogenesis. As there
exist the other transcription factors, such as activator protein-2,
whose transcriptional activity is promoted by cAMP (Garcia et al,
1999), it should further be clari®ed if the cAMP-responsive
transcription factors other than CREB/ATF-1 can also be the
targets for ketoconazole.
It is reported that EP2 and EP4 among four identi®ed PGE2
receptor isoforms are positively coupled to AC via guanine
nucleotide-binding proteins (Maldve et al, 2000). Thus PGE2-
induced activation of AC may be mediated through either or
both of EP2 and EP4 in A-431 cells. The mechanism for PGE2-
induced COX-2 expression is similar to that for an AC catalyst
activator forskolin; forskolin enhanced PKA-mediated phos-
phorylation of CREB/ATF-1 by inducing cAMP signal and
thus promoted COX-2 transcription in HaCaT cells (Tang et al,
2001). Another mechanism is also reported for cAMP-induced
COX-2 transcription; cAMP-elevating agents, forskolin, lutei-
nizing hormone, and follicle-stimulating hormone promoted C/
EBPb synthesis and enhanced C/EBPb-mediated COX-2
transcription through C/EBP element in rat granulosa cells
(Sirois and Richards, 1993). This mechanism is, however,
unlikely for A-431 cells as PGE2 did not enhance C/EBP-
dependent transcription in these cells (Fig 4). It is also reported
that PGE2 enhanced C/EBPd-mediated insulin-like growth
factor-I gene expression through C/EBP element in rat
osteoblasts (Umayahara et al, 1997). C/EBPd binds to both
C/EBP and CRE sites on human COX-2 promoter (Inoue et
al, 1995), and C/EBPd-mediated COX-2 transcription is
enhanced in murine skin carcinoma cells (Kim and Fischer,
1998). C/EBPd, however, may not be involved in PGE2-
induced COX-2 transcription in A-431 cells as C/EBPd did
not form a complex with the COX-2 CRE probe (Fig 5b) and
PGE2 did not enhance C/EBP-dependent transcription in these
cells (Fig 4).
Takahashi et al (1994) and Pilbeam et al (1995) also reported that
PGF2a promoted COX-2 expression by inducing phosphatidyli-
nositol turnover in murine osteoblastic cell lines. The binding of
PGF2a to its receptor may activate phospholipase C, and may
further promote the activity of downstream protein kinase C,
which may enhance the activity of certain transcription factors,
such as NF-kB or c-Jun to induce COX-2 expression. Among the
receptors for PGE2, EP1 and several isoforms of EP3 are coupled to
phospholipase C (Pilbeam et al, 1995). Thus it is also possible that
PGE2 may induce COX-2 transcription via EP1 or EP3-mediated
activation of phospholipase C/protein kinase C pathway. This
mechanism is, however, unlikely for A-431 cells as EP1/EP3
receptor agonist sulprostone did not induce COX-2 transcription
in A-431 cells (unpublished observations). An alternative mechan-
ism for PGE2-induced COX-2 expression involves the peroxisome
proliferator response element. Several prostaglandins are ligands for
nuclear peroxisomal proliferator-activated receptors, and the
ligand-bound peroxisomal proliferator-activated receptor hetero-
dimerizes with nuclear retinoic acid X receptor, and the
heterodimer binds to a peroxisome proliferator response element
on certain genes, and induces the gene expression (Meade et al,
1999). 5¢-¯anking region of COX-2 gene contains the peroxisome
proliferator response element at approximately 3900 bases upstream
of the transcriptional start site, and peroxisome proliferator WY-
14643 enhanced COX-2 transcription through this element in
human mammary epithelial cells (Meade et al, 1999). Thus it should
be examined if prostaglandins, including PGE2, may also use this
mechanism for COX-2 expression in A-431 cells.
Several studies reported that PGE2 or other cAMP-elevating
agents inhibited COX-2 expression; PKA inhibited the phos-
phorylation of c-Jun transcription factor by c-Jun NH2-terminal
kinase (Hsueh and Lai, 1995), which led to the inhibition of c-Jun-
mediated COX-2 transcription in porcine aortic smooth muscle
cells (Karim et al, 1997). In A-431 cells, however, such a manner of
inhibition may not occur as c-Jun did not bind to CRE on COX-2
promoter in these cells (Fig 5b). It is also reported that PKA
inhibits the activity of extracellular signal-regulated kinase (Shapiro
et al, 1996), which phosphorylates C/EBPb and promotes the C/
EBPb-mediated COX-2 transcription through C/EBP element in
murine mast cells (Reddy et al, 2000). Thus it is possible that PGE2
may suppress the C/EBPb-mediated COX-2 transcription by
activating PKA. This possibility is also unlikely for A-431 cells as
PGE2 did not suppress C/EBP-dependent COX-2 transcription in
these cells (Fig 4). It appears that PGE2 may regulate COX-2
expression in a cell-type-speci®c and species-speci®c manner. The
upregulation or downregulation of COX-2 expression by PGE2
and the mechanism for the regulation may depend on the amounts
and activities of the relevant transcriptional activators, repressors,
and cofactors, and also on the activities of signaling molecules
regulating these factors. At least in A-431 cells, PGE2 enhanced
phospho-CREB/ATF-1-mediated COX-2 expression via cAMP.
It should further be elucidated whether PGE2 may upregulate or
downregulate COX-2 expression in the other skin cancer cells and
also determine what the precise mechanisms for this regulation are.
In this study, PGE2 did not alter COX-1 expression (Fig 1) and the
results are different from those in murine keratinocytes showing the
enhancement of COX-1 expression by PGE2 (Maldve et al, 2000).
This may be due to the difference in the sequences of COX-1 gene
between species and also due to the aberrant regulation associated
with carcinogenesis; the PGE2-mediated promotion of COX-1
expression may be suppressed in cancer cells by a speci®c unde®ned
mechanism.
This study suggests that ketoconazole may inhibit PGE2-driven
positive feedback control of COX-2 expression. This effect of
ketoconazole may prevent the sustained COX-2 expression and
may lead to the inhibition on the growth of skin cancer. It is
reported that COX-2-induced carcinogenesis consists of PGE2-
dependent and PGE2-independent pathways (Higashi et al, 2000).
COX possesses COX activity converting arachidonic acid to
PGG2, and peroxidase activity generating PGH2, a direct precursor
of PGE2, from PGG2. In addition to its role in PG synthesis, the
peroxidase activity of COX contributes to superoxide production
and subsequent alteration in intracellular redox status, which is
associated with perturbations of cell growth and transformation
(Higashi et al, 2000). Thus ketoconazole-induced inhibition of
COX-2 expression may prevent both PGE2-dependent and PGE2-
independent pathways for carcinogenesis. Thus ketoconazole may
be more effective for the inhibition of cancer growth than the
inhibitors of COX-2 catalytic activity, such as NS-398, which
inhibits COX activity but not the peroxidase activity of COX-2. A
recent study showed that COX-2 expression was detectable in
premalignant lesions, such as actinic keratoses (Muller-Decker et al,
1999). Ketoconazole, therefore, may manifest chemopreventive
effects to suppress the progression from such premalignant lesions
into a more advanced status by inhibiting COX-2 expression.
Previous studies revealed the anti-cancer effects of ketoconazole via
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inhibition of cytochrome P450-dependent enzymes (Janssen et al,
1989). Taken together, ketoconazole may inhibit the multiple
carcinogenic pathways dependent on cytochrome P450 and on
AC.
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